A clinical case of the Wada test in a patient with structural pharmacoresistant epilepsy

Wada test is an effective diagnostic method for determining the hemispheric localization of speech functions. The vast majority of epileptological centers use this technique in pre-surgical diagnosis in adult patients with medial temporal lobe epilepsy. According to international literature, the use of this test in the pediatric population is extremely rare due to the need for adequate contact with the patient. We present a clinical case of a patient with structural pharmacoresistant epilepsy caused by post-stroke changes in the left middle cerebral artery. Wada test was used as part of a pre-surgical examination to determine the lateralization of the patient’s speech function. The test results allowed determining the right hemisphere to be  dominant in speech function. After the surgical intervention — transylviar periinsular functional hemispherectomy — the girl had no deterioration in speech functions, which confirmed the specificity and sensitivity of the Wada test in a child with impaired cognitive development.

Contribution:
Russkin V.O. — concept, writing text, editing;
Kuznetsova A.A. — concept, writing text, editing;
Solovyov V.B. — concept, editing;
Levov A.V. — concept;
Schederkina I.O. — writing text, editing;
Livshits M.I. — concept.
All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: May 12, 2023
Accepted: August 30, 2023
Published: October 13, 2023

1. Löscher W., Potschka H., Sisodiya S.M., Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol. Rev. 2020; 72(3): 606–38. https://doi.org/10.1124/pr.120.019539

2. Krylov V.V., Gekht A.B., Trifonov I.S., Lebedeva A.V., Kaymovskiy I.L., Sinkin M.V., et al. Outcomes of surgical treatment of patients with pharmacoresistant epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016; 116(9‑2): 13–8. https://doi.org/10.17116/jnevro20161169213-18 https://elibrary.ru/xeejbd (in Russian)

3. Fattorusso A., Matricardi S., Mencaroni E., Dell’Isola G.B., Di Cara G., Striano P., et al. The Pharmacoresistant epilepsy: an overview on existant and new emerging therapies. Front. Neurol. 2021; 12: 674483. https://doi.org/10.3389/fneur.2021.674483

4. Lerche H. Drug-resistant epilepsy – time to target mechanisms. Nat. Rev. Neurol. 2020; 16(11): 595–6. https://doi.org/10.1038/s41582-020-00419-y

5. Lebedeva A.V., Avedisova A.S., Kustov G.V., Gersamiya A.G., Kaymovskiy I.L., Rider F.K., et al. Prognosis for surgical treatment of pharmacoresistant epilepsy: the role of mental and cognitive disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018; 118(10-2): 27–36. https://doi.org/10.17116/jnevro201811810227 https://elibrary.ru/ywjqup (in Russian)

6. Tang F., Hartz A.M.S., Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front. Neurol. 2017; 8: 301. https://doi.org/10.3389/fneur.2017.00301

7. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies. Epilepsia. 2010; 51(6): 1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x

8. Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L., et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512–21. https://doi.org/10.1111/epi.13709

9. Ayvazyan S.O., Shiryaev Yu.S. Modern treatment of drug-resistant epilepsy, available in Russian Federation. Epilepsiya i paroksizmal’nye sostoyaniya. 2016; 8(1): 22–8. https://doi.org/10.17749/2077-8333.2016.8.1.022-028 https://elibrary.ru/whovhd (in Russian)

10. Karami M., Mehvari Habibabadi J., Nilipour R., Barekatain M., Gaillard W.D., Soltanian-Zadeh H. Presurgical language mapping in patients with intractable epilepsy: a review study. Basic Clin. Neurosci. 2021; 12(2): 163–76. https://doi.org/10.32598/bcn.12.2.2053.1

11. Walker J.A., Quiñones-Hinojosa A., Berger M.S. Intraoperative speech mapping in 17 bilingual patients undergoing resection of a mass lesion. Neurosurgery. 2004; 54(1): 113–7. https://doi.org/10.1227/01.neu.0000097270.95721.3b

12. de Ribaupierre S., Wang A., Hayman-Abello S. Language mapping in temporal lobe epilepsy in children: special considerations. Epilepsy Res. Treat. 2012; 2012: 837036. https://doi.org/10.1155/2012/837036

13. Jansen F.E., Jennekens-Schinkel A., Van Huffelen A.C., Van Veelen W.M., Van Rijen C.P., Alpherts W.C., et al. Diagnostic significance of Wada procedure in very young children and children with developmental delay. Eur. J. Paediatr. Neurol. 2002; 6(6): 315–20. https://doi.org/10.1016/s1090-3798(02)90619-7

14. Liégeois F., Connelly A., Helen Cross J., Boyd S.G., Gadian D.G., Vargha‐Khadem F., et al. Language reorganization in children with early‐onset lesions of the left hemisphere: an fMRI study. Brain. 2004; 127(Pt. 6): 1229–36. https://doi.org/10.1093/brain/awh159

15. Hamer H.M., Wyllie E., Stanford L., Mascha E., Kotagal P., Wolgamuth B. Risk factors for unsuccessful testing during the intracarotid amobarbital procedure in preadolescent children. Epilepsia. 2000; 41(5): 554–63. https://doi.org/10.1111/j.1528-1157.2000.tb00209.x

16. Greiner H.M., Park Y.D., Holland K., Horn P.S., Byars A.W., Mangano F.T., et al. Scalp EEG does not predict hemispherectomy outcome. Seizure. 2011; 20(10): 758–63. https://doi.org/10.1016/j.seizure.2011.07.006

17. McCleary K., Barrash J., Granner M., Manzel K., Greider A., Jones R. The safety and efficacy of propofol as a replacement for amobarbital in intracarotid Wada testing of presurgical patients with epilepsy. Epilepsy Behav. 2018; 78: 25–9. https://doi.org/10.1016/j.yebeh.2017.10.037

18. Takayama M., Miyamoto S., Ikeda A., Mikuni N., Takahashi J.B., Usui K., et al. Intracarotid propofol test for speech and memory dominance in man. Neurology. 2004; 63(3): 510–5. https://doi.org/10.1212/01.wnl.0000133199.65776.18